KAPA
Kairos Pharma, LTD.
$0.37
+0.00 (+0.54%)
At close · Jul 2
Market Cap
$7.92M
Shares
21,411,198
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.37
Open$0.36
Day$0.36–0.39
52W$0.33–2.11
Avg vol 30d119K
Short int155K · 0.7% float · 1.3d
Short vol57%
DataSep 2024–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−50% below
−
Price vs 50-day avg
−25% below
◦
RSI (14)
34 · neutral
−
MACD trend
negative
−
52-week position
3% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $1 — 200d above 50d
−
Institutional flow
-21% holders QoQ · +4 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.72% of float · ▼ -1.5% MoM · 1.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
11 holders — mid 1-yr range
Fundamentals
Fair
−
EPS growth
−30% Y/Y
+
Balance sheet
net cash $4.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−50% below
Bearish
Price vs 50-day avg
−25% below
Bearish
RSI (14)
34 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
3% · near low
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-21% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.72% of float · ▼ -1.5% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
11 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 3%
52-wk high $2
vs 200-day avg -50%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KAPA
this stock
Kairos Pharma, LTD.
|
$7.92M | -47.9% | — | — | 0.7% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KAPA | -1.3% | -19.9% | -61.9% | -3.7% | -47.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -2.8% | -18.7% | -69.9% | -3.4% | -57.1% |